Degarelix
DB06699
Approved Indication
Degaralix is used for the management of advanced prostate cancer.
1
Targets
0
Resistance Mutations
2
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
GnRH antagonists compete with natural GnRH for binding to GnRH receptors in the pituitary gland. This reversible blinding blocks the release of LH and FSH from the pituitary. The reduction in LH subsequently leads to a rapid and sustained suppression of testosterone release from the testes and subsequently reduces the size and growth of the prostate cancer.
Details
DrugBank ID
DB06699 ↗
Approval Date
2009-03-02
Molecular Weight
1632.29 g/mol
Drug Class
Other
ATC Codes
L02BX02
Synonyms
—
PubChem
CID: 16136245 ↗
ChEMBL
CHEMBL415606 ↗
SMILES
CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
ADMET Profile
Computing properties…
Drug References (DrugBank)